Patriot Financial Group Insurance Agency LLC decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 23.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,658 shares of the company’s stock after selling 6,928 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in CRISPR Therapeutics were worth $892,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in CRSP. Capital Market Strategies LLC bought a new position in CRISPR Therapeutics in the 4th quarter worth approximately $461,000. Capital Advisors Inc. OK grew its stake in shares of CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after purchasing an additional 22,583 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares during the period. Granite Bay Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics during the second quarter valued at about $2,375,000. Finally, State Street Corp lifted its holdings in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.
CRISPR Therapeutics Stock Performance
Shares of CRSP opened at $41.81 on Wednesday. The company has a market capitalization of $3.57 billion, a PE ratio of -14.77 and a beta of 1.68. The company’s 50 day moving average price is $44.09 and its 200 day moving average price is $47.46. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on CRSP. Barclays dropped their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Bank of America reduced their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Chardan Capital reiterated a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $78.38.
Get Our Latest Report on CRISPR Therapeutics
Insider Transactions at CRISPR Therapeutics
In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.10% of the company’s stock.
CRISPR Therapeutics Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
See Also
- Five stocks we like better than CRISPR Therapeutics
- Why Invest in High-Yield Dividend Stocks?
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is Put Option Volume?
- What Does the Future Hold for Eli Lilly?
- Why Are These Companies Considered Blue Chips?
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report).
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.